RESUMEN
Gyrate atrophy of the choroid and retina (GACR) is a rare autosomal recessive disease characterised by elevated plasma ornithine levels due to deficiency of the enzyme ornithine aminotransferase (OAT). The accumulation of this amino acid in plasma leads to the development of patches of chorioretinal atrophy in the peripheral retina extending into the macular area. Patients usually present with night blindness followed by constriction of the visual field and, finally, decreased central vision and blindness. The disease is diagnosed by the presence of the characteristic clinical picture, the presence of hyperornithinaemia in plasma and the detection of mutations in the OAT enzyme gene. There is currently no effective gene therapy and the most common therapeutic intervention mainly involves dietary modifications with arginine restriction. This article aims to summarise the pathogenesis, clinical and diagnostic findings and treatment options in patients with GACR.
Asunto(s)
Atrofia Girata , Humanos , Atrofia Girata/diagnóstico , Atrofia Girata/terapia , Ornitina-Oxo-Ácido Transaminasa/deficiencia , Ornitina-Oxo-Ácido Transaminasa/genética , Ornitina/uso terapéutico , Arginina/uso terapéuticoRESUMEN
l-Ornithine (Orn) is a core amino acid responsible for ammonia detoxification in the body via the hepatic urea cycle. Clinical studies in Orn therapy have focused on interventions for hyperammonemia-associated diseases, such as hepatic encephalopathy (HE), a life-threatening neurological symptom affecting more than 80% of patients with liver cirrhosis. However, its low molecular weight (LMW) causes Orn to diffuse nonspecifically and be rapidly eliminated from the body after oral administration, resulting in unfavorable therapeutic efficacy. Hence, Orn is constantly supplied by intravenous infusion in many clinical settings; however, this treatment inevitably decreases patient compliance and limits its application in long-term management. To improve the performance of Orn, we designed self-assembling polyOrn-based nanoparticles for oral administration through ring-opening polymerization of Orn-N-carboxy anhydride initiated with amino-ended poly(ethylene glycol), followed by acylation of free amino groups in the main chain of the polyOrn segment. The obtained amphiphilic block copolymers, poly(ethylene glycol)-block-polyOrn(acyl) (PEG-block-POrn(acyl)), enabled the formation of stable nanoparticles (NanoOrn(acyl)) in aqueous media. We employed the isobutyryl (iBu) group for acyl derivatization in this study (NanoOrn(iBu)). In the healthy mice, daily oral administration of NanoOrn(iBu) for one week did not induce any abnormalities. In the mice exhibiting acetaminophen (APAP)-induced acute liver injury, oral pretreatment with NanoOrn(iBu) effectively reduced systemic ammonia and transaminases levels compared to the LMW Orn and untreated groups. The results suggest that the application of NanoOrn(iBu) is of significant clinical value with the feasibility of oral delivery and improvement in APAP-induced hepatic pathogenesis. STATEMENT OF SIGNIFICANCE: Liver injury is often accompanied by hyperammonemia, a life-threatening condition characterized by elevated blood ammonia levels. Current clinical treatments for reducing ammonia typically entail the invasive approach of intravenous infusion, involving the administration of l-ornithine (Orn) or a combination of Orn and L-aspartate. This method is employed due to the poor pharmacokinetics associated with these compounds. In our pursuit of enhancing therapy, we have developed an orally administrable nanomedicine based on Orn-based self-assembling nanoparticle (NanoOrn(iBu)), which provides sustained Orn supply to the injured liver. Oral administration of NanoOrn(iBu) to healthy mice did not cause any toxic effects. In a mouse model of acetaminophen-induced acute liver injury, oral administration of NanoOrn(iBu) surpassed Orn in reducing systemic ammonia levels and liver damage, thereby establishing NanoOrn(iBu) as a safe and effective therapeutic option.
Asunto(s)
Hiperamonemia , Ratones , Animales , Hiperamonemia/inducido químicamente , Hiperamonemia/complicaciones , Hiperamonemia/tratamiento farmacológico , Ornitina/farmacología , Ornitina/uso terapéutico , Ornitina/metabolismo , Acetaminofén/farmacología , Polímeros/farmacología , Amoníaco/metabolismo , Amoníaco/farmacología , Nanomedicina , Hígado , Polietilenglicoles/farmacologíaRESUMEN
DESCRIPCIÓN DEL PROBLEMA DE SALUD: La cirrosis es un trastorno crónico del hígado. Los pacientes con esta afección desarrollan por lo general encefalopatía hepática, una complicación que da lugar a un funcionamiento cerebral deficiente. Algunos pacientes con cirrosis desarrollan características clínicas obvias de una alteración en el funcionamiento cerebral, como dificultades con el habla, el equilibrio y el funcionamiento diario; se dice que presentan encefalopatía hepática evidente; los cambios pueden ser transitorios, recurrentes o pueden persistir durante períodos prolongados. Otros pacientes con cirrosis pueden no mostrar cambios obvios, aunque al realizarles pruebas se pueda encontrar que algunos aspectos clínicos de la función cerebral, como la atención y la capacidad para cumplir tareas complejas, presentan un deterioro; se dice que presentan encefalopatía hepática mínima. La razón por la que los pacientes desarrollan encefalopatía hepática es compleja, pero la acumulación en sangre de toxinas de los intestinos, en particular de un compuesto llamado amoníaco, desempeña una función clave. La L-ornitina L-aspartato reduce los niveles de amoníaco en sangre y, por lo tanto, puede tener efectos beneficiosos en los pacientes con encefalopatía hepática o ayudar a interrumpir su desarrollo. METODOLOGÍA: Se realizó una búsqueda en las principales bases de datos bibliográficas Pubmed: L-ornithine L-aspartate and/or, Dipeptides [adverse effects, *therapeutic use]; Hepatic Encephalopathy [*drug therapy, mortality, *prevention & control]; Liver Cirrhosis [*complications]; Quality of Life; Randomized Controlled Trials as Topic; Branched Chain Amino Acid Supplementation; Probiotics; Lactulose; Placebo; Lactitol; Antibiotic Therapy. Se filtró la búsqueda a Estudios Clínicos fase III, controlados randomizados, Revisiones Sistemáticas, Meta-análisis, Guías de Práctica Clínica, además se limitó la búsqueda estudios en humanos. También se realizó búsqueda manual en otras bases de datos bibliográficas (Cochrane, NIH, TRIP DATABASE), en buscadores genéricos de internet, agencias de evaluación de tecnologías sanitarias y financiadores de salud. Se priorizó la inclusión de revisiones sistemáticas, meta-análisis, estudios clínicos aleatorizados y controlados, guías de práctica clínica, evaluaciones de tecnología sanitaria, evaluaciones económicas y políticas de cobertura de otros sistemas de salud. CONCLUSIONES: Eficacia: L-Ornitina-L-Asparato (LOLA) ha sido utilizada como tratamiento para pacientes con hepatopatía crónica con riesgo de encefalopatía hepática. La evaluación de la eficacia de LOLA en esta población se ha basado en estudios clínicos controlados y aleatorizados. En general, la evidencia disponible sugiere que LOLA puede ser eficaz en la prevención y tratamiento de la encefalopatía hepática en pacientes con hepatopatía crónica. En varios estudios clínicos se ha observado que el uso de LOLA se asocia con una reducción significativa en la incidencia de la encefalopatía hepática y una mejora en la calidad de vida de los pacientes. Por ejemplo, un estudio aleatorizado, doble ciego y controlado con placebo realizado en 2011 demostró que LOLA redujo significativamente la incidencia de encefalopatía hepática en pacientes con cirrosis hepática avanzada. Otro estudio aleatorizado y controlado, publicado en 2015, encontró que el uso de LOLA se asoció con una mejora significativa en la calidad de vida de los pacientes con encefalopatía hepática. Sin embargo, es importante tener en cuenta que algunos estudios han reportado resultados contradictorios, y la evidencia global sobre la eficacia de LOLA es limitada y no concluyente. Además, la mayoría de los estudios han sido realizados en poblaciones específicas y pueden no ser generalizables a otras poblaciones. Seguridad: Según la revisión sistemática y metaanálisis analizados, se concluye que la L-Ornitina-L-Asparato es segura en la dosis recomendada para pacientes con cirrosis hepática y encefalopatía hepática. En los estudios revisados, no se reportaron efectos adversos graves asociados con el uso de LOrnitina-L-Asparato, y los efectos secundarios menores (como diarrea y náuseas) se presentaron en una proporción similar entre el grupo de tratamiento y el grupo de control. Además, otros estudios investigados compararon la seguridad de la L-Ornitina-L-Asparato con la lactulosa (un tratamiento convencional para la encefalopatía hepática) en pacientes con cirrosis hepática y encefalopatía hepática. Los resultados indicaron que la L-Ornitina-L-Asparato y la lactulosa fueron igualmente seguras, y que no hubo diferencias significativas en la frecuencia o gravedad de los efectos adversos entre ambos tratamientos. Conveniencia: Las ventajas de utilizar las diferentes opciones terapéuticas dependen de la condición específica del paciente. Tanto la lactulosa como la rifaximina se administran por vía oral, sin embargo, en casos donde la vía oral está comprometida, las ampollas endovenosas de L-ornitina-L-aspartato se convierten en la opción más viable. Costo: Aunque el costo por tratamiento completo puede ser más alto que otras opciones terapéuticas, la eficacia y seguridad de L-Ornitina-L-Asparato lo convierten en una opción atractiva desde el punto de vista costo-efectividad. Además, si se logra prevenir la encefalopatía hepática, los costos a largo plazo para el tratamiento de esta condición serían mucho mayores. Además, considerando los beneficios que se han demostrado en cuanto a la eficacia y seguridad del tratamiento, especialmente en pacientes con encefalopatía hepática de grado leve a moderado, podemos concluir que el uso de L-Ornitina-L-Aspartato es una opción costo-efectiva para el tratamiento de estos pacientes en el contexto del Instituto Salvadoreño del Seguro Social. Es importante tener en cuenta que la evaluación de costo-efectividad no solo se basa en el costo del tratamiento, sino también en la eficacia y los beneficios que se obtienen a través de su uso. En este caso, se ha demostrado que el uso de L-Ornitina-L-Aspartato tiene un impacto positivo en la reducción de los síntomas de encefalopatía hepática y la calidad de vida de los pacientes, lo que puede justificar su uso en términos de costo-efectividad.
Asunto(s)
Humanos , Ornitina/uso terapéutico , Encefalopatía Hepática/tratamiento farmacológico , Ácido Aspártico/uso terapéutico , Evaluación en Salud/economía , EficaciaRESUMEN
Lysinuric protein intolerance (LPI) is a rare metabolic disorder with reduced renal and intestinal reabsorption of ornithine, lysine, and arginine. It is due to variants in SLC7A7, the gene encoding y+L amino acid transporter 1 (y+LAT1), which lead to urea cycle defects with protein intolerance. Chronic kidney disease in lysinuric protein intolerance is common and can progress to kidney failure and initiation of kidney replacement therapy. Kidney transplantation could in theory improve urine levels and, consequently, plasma levels of these amino acids and therefore improve clinical symptoms, as well as protein intolerance, in patients with lysinuric protein intolerance. However, data on kidney transplantation in patients with lysinuric protein intolerance are limited, and up until now no data on clinical and biochemical improvement after kidney transplantation have been reported. In this case report we describe a rare case of kidney transplantation in a lysinuric protein intolerance patient with substantial improvement in protein tolerance; in plasma and urine levels of ornithine, lysine, and arginine; and in lysinuric protein intolerance symptoms.
Asunto(s)
Errores Innatos del Metabolismo de los Aminoácidos , Trasplante de Riñón , Enfermedades Metabólicas , Humanos , Lisina/orina , Errores Innatos del Metabolismo de los Aminoácidos/complicaciones , Errores Innatos del Metabolismo de los Aminoácidos/tratamiento farmacológico , Errores Innatos del Metabolismo de los Aminoácidos/genética , Arginina/uso terapéutico , Arginina/metabolismo , Ornitina/uso terapéutico , Sistema de Transporte de Aminoácidos y+LRESUMEN
We hypothesized that the enzyme arginase-1 is released into the cerebrospinal fluid (CSF) during red blood cell lysis and contributes to dysregulated metabolism of the nitric oxide (NO) precursor L-arginine during aneurysmal subarachnoid hemorrhage (SAH). This prospective case-control study included 43 patients with aneurysmal SAH and ventricular drainage for clinical reasons. Longitudinal CSF samples (99) were obtained in the course of SAH. Patients were dichotomized regarding the occurrence of cerebral vasospasm syndrome (CVS) (N = 19). Arginase-1 and the amino acids L-arginine and L-ornithine were quantified in CSF. Outcome assessments included delayed cerebral ischemia (DCI) and functional status after 3 months using the modified Rankin Scale (mRS). Arginase-1 was released into the CSF of SAH patients whereas this enzyme was undetectable in controls. Compared to patients without CVS, arginase-1 levels were higher in CVS patients until day 14 after clinical event. The well-known surrogate parameter for arginase acitivity, the L-arginine to L-ornithine ratio (Arg/Orn), correlated with CSF arginase-1 levels. Arg/Orn was reduced in patients with CVS from disease onset (days 1-3, p = 0.0009) until day 14. Logistic regression analysis of early Arg/Orn was predictive for CVS (p = 0.008) and DCI (p = 0.035), independent of age, Hunt and Hess grade, and intraventricular blood. Arg/Orn < 2.71 at disease onset predicted CVS with a sensitivity of 86.7% and specificity of 72.2%. Arg/Orn ≥ 2.71 predicted excellent functional outcome. We propose a novel mechanism contributing to NO deprivation during SAH: arginase-1 is released from erythrocytes into the CSF, leading to L-arginine consumption and reduced NO bioavailability. Furthermore, Arg/Orn is a robust predictor for occurrence of CVS, DCI, and functional outcome 3 months after aneurysmal SAH. Our data provide a novel prognostic biomarker and may contribute to the development of novel therapeutic strategies in SAH. Clinical Trial Registration-URL: http://www.drks.de . Unique identifier: DRKS00015293, date of registration: 13.09.2018.
Asunto(s)
Isquemia Encefálica , Hemorragia Subaracnoidea , Vasoespasmo Intracraneal , Arginasa , Arginina , Biomarcadores , Estudios de Casos y Controles , Infarto Cerebral , Humanos , Óxido Nítrico , Ornitina/uso terapéutico , Pronóstico , Hemorragia Subaracnoidea/líquido cefalorraquídeo , Vasoespasmo Intracraneal/etiologíaRESUMEN
BACKGROUND AND OBJECTIVE: L-Ornithine phenylacetate is an intravenous formulation of the L-ornithine salt of phenylacetic acid under development for the treatment of hepatic encephalopathy. Very limited clinical data in patients are available, with a phase II study in target patients not designed for dose finding, to support phase III dose selection in a global development program. The objective of the present population pharmacokinetic modeling and simulation was to evaluate dose selection for target patient populations with a low body weight, ethnicity, and hepatic impairment in a global clinical study. METHODS: A population pharmacokinetic model was developed based on plasma concentrations of L-ornithine, phenylacetic acid, and phenylacetylglutamine data from four clinical trials in healthy subjects and patients with stable cirrhosis or hospitalized adult patients with liver cirrhosis and hepatic encephalopathy. A covariate analysis was conducted to identify source of variability to support dose selection for global clinical development of L-ornithine phenylacetate. Phenylacetylglutamine formation in the pharmacokinetic model also quantified pharmacodynamic effects measured by ammonia removal. RESULTS: Body weight and hepatic function were significant covariates determining phenylacetic acid exposure. After accounting for body weight, there was no difference between tested Caucasian and Asian populations in phenylacetic acid exposure. Renal dysfunction significantly reduced phenylacetylglutamine excretion. However, renal impairment had no impact on plasma phenylacetic acid and free ammonia levels. Exploratory modeling suggested that L-ornithine might enhance the removal of ammonia. CONCLUSIONS: With a flat dosing algorithm, special consideration must be given to patients with a small body size (i.e., body weight ≤ 50 kg) and severe hepatic impairment.
Asunto(s)
Encefalopatía Hepática , Fenilacetatos , Adulto , Amoníaco/uso terapéutico , Ensayos Clínicos como Asunto , Encefalopatía Hepática/tratamiento farmacológico , Humanos , Ornitina/farmacología , Ornitina/uso terapéutico , Fenilacetatos/farmacología , Fenilacetatos/uso terapéuticoRESUMEN
Overt hepatic encephalopathy is a generally reversible neurologic complication of cirrhosis. Overt hepatic encephalopathy has been associated with poor hospitalization- and mortality-related outcomes, which is important given increasing hepatic encephalopathy-related hospitalizations over time. The aim of this narrative review is to provide an overview of hospital- and mortality-related outcomes in patients with overt hepatic encephalopathy and the pharmacologic therapies that may improve these outcomes. Guideline-recommended prophylaxis with lactulose (first-line therapy) or secondary prophylaxis with rifaximin plus lactulose decreases hospital admissions and mortality rates. Rifaximin or lactulose treatment was beneficial for reducing the hospitalization rate in patients with hepatic encephalopathy compared with no treatment. Further, retrospective studies have shown that rifaximin with or without lactulose was effective for decreasing the number of hepatic encephalopathy episodes, hepatic encephalopathy-related hospitalizations, and duration of hospitalization. Ornithine phenylacetate, an ammonia-reducing agent currently in development, is also being investigated in hospitalized patients with hepatic encephalopathy. Overall, data support that prophylaxis for the prevention of hepatic encephalopathy recurrence improves outcomes in patients with cirrhosis and a history of hepatic encephalopathy.
Asunto(s)
Fármacos Gastrointestinales/uso terapéutico , Encefalopatía Hepática/prevención & control , Lactulosa/uso terapéutico , Ornitina/análogos & derivados , Rifaximina/uso terapéutico , Encefalopatía Hepática/tratamiento farmacológico , Hospitalización/estadística & datos numéricos , Humanos , Tiempo de Internación , Mortalidad , Ornitina/uso terapéutico , Prevención SecundariaRESUMEN
Background: Neutrophil extracellular traps (NETs) have been implicated in host immune responses. Attempts have been made to examine how NETs affect the pathogenesis of complications such as autoimmune and vascular disorders. Aim: This study aimed to explore the relationship between NETs and vasculitis. Material and Methods: The current study entailed the searching of PsycINFO, PubMed, Web of Science, and CINAHL for articles related to the research topic. The search terms and phrases included "vasculitis," "NETs," "neutrophil extracellular traps," "NETosis," and "pathogenesis." The search was limited to articles published between 2009 and 2019. Results: Researchers have shown that NETs contribute to the pathogenesis of vasculitis through different mechanisms and processes, including renal failure and vascular damage. The protective effects of NETs have also been highlighted. Discussion: Overall, some scholars have shown the effectiveness of using DNase I and the PAD4 inhibitor Cl-amidine to treat vasculitis by restricting NET formation. However, observations have been noted in only animal experimental models. Conclusion: Neutrophil hyperactivity and its role in vasculitis are not yet fully understood. More studies aiming to determine the accurate function of NETs in vasculitis pathogenesis, particularly in humans, should be undertaken. Intensive research on NETs and vasculitis can increase the knowledge of medical practitioners and contribute to the development of new treatment methods to enhance patient outcomes in the future.
Asunto(s)
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/inmunología , Trampas Extracelulares/inmunología , Arteritis de Células Gigantes/inmunología , Neutrófilos/inmunología , Arteritis de Takayasu/inmunología , Animales , Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/sangre , Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/tratamiento farmacológico , Apoptosis , Desoxirribonucleasa I/farmacología , Desoxirribonucleasa I/uso terapéutico , Modelos Animales de Enfermedad , Trampas Extracelulares/efectos de los fármacos , Arteritis de Células Gigantes/sangre , Arteritis de Células Gigantes/tratamiento farmacológico , Humanos , Neutrófilos/citología , Neutrófilos/efectos de los fármacos , Neutrófilos/patología , Ornitina/análogos & derivados , Ornitina/farmacología , Ornitina/uso terapéutico , Arginina Deiminasa Proteína-Tipo 4/antagonistas & inhibidores , Arginina Deiminasa Proteína-Tipo 4/metabolismo , Muerte Celular Regulada/efectos de los fármacos , Muerte Celular Regulada/inmunología , Arteritis de Takayasu/sangre , Arteritis de Takayasu/tratamiento farmacológicoRESUMEN
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies with limited survival rate. Roles for peptidylarginine deiminases (PADs) have been studied in relation to a range of cancers with roles in epigenetic regulation (including histone modification and microRNA regulation), cancer invasion, and extracellular vesicle (EV) release. Hitherto though, knowledge on PADs in PDAC is limited. In the current study, two PDAC cell lines (Panc-1 and MiaPaCa-2) were treated with pan-PAD inhibitor Cl-amidine as well as PAD2, PAD3, and PAD4 isozyme-specific inhibitors. Effects were assessed on changes in EV signatures, including EV microRNA cargo (miR-21, miR-126, and miR-221), on changes in cellular protein expression relevant for pancreatic cancer progression and invasion (moesin), for mitochondrial housekeeping (prohibitin, PHB), and gene regulation (deiminated histone H3, citH3). The two pancreatic cancer cell lines were found to predominantly express PAD2 and PAD3, which were furthermore expressed at higher levels in Panc-1, compared with MiaPaCa-2 cells. PAD2 isozyme-specific inhibitor had the strongest effects on reducing Panc-1 cell invasion capability, which was accompanied by an increase in moesin expression, which in pancreatic cancer is found to be reduced and associated with pancreatic cancer aggressiveness. Some reduction, but not significant, was also found on PHB levels while effects on histone H3 deimination were variable. EV signatures were modulated in response to PAD inhibitor treatment, with the strongest effects observed for PAD2 inhibitor, followed by PAD3 inhibitor, showing significant reduction in pro-oncogenic EV microRNA cargo (miR-21, miR-221) and increase in anti-oncogenic microRNA cargo (miR-126). While PAD2 inhibitor, followed by PAD3 inhibitor, had most effects on reducing cancer cell invasion, elevating moesin expression, and modulating EV signatures, PAD4 inhibitor had negligible effects and pan-PAD inhibitor Cl-amidine was also less effective. Compared with MiaPaCa-2 cells, stronger modulatory effects for the PAD inhibitors were observed in Panc-1 cells, which importantly also showed strong response to PAD3 inhibitor, correlating with previous observations that Panc-1 cells display neuronal/stem-like properties. Our findings report novel PAD isozyme regulatory roles in PDAC, highlighting roles for PAD isozyme-specific treatment, depending on cancer type and cancer subtypes, including in PDAC.
Asunto(s)
Carcinoma Ductal Pancreático/patología , Vesículas Extracelulares/metabolismo , Neoplasias Pancreáticas/patología , Arginina Deiminasa Proteína-Tipo 2/metabolismo , Arginina Deiminasa Proteína-Tipo 3/metabolismo , Carcinoma Ductal Pancreático/tratamiento farmacológico , Línea Celular Tumoral , Vesículas Extracelulares/efectos de los fármacos , Humanos , Isoenzimas/antagonistas & inhibidores , Isoenzimas/metabolismo , Invasividad Neoplásica/patología , Ornitina/análogos & derivados , Ornitina/farmacología , Ornitina/uso terapéutico , Neoplasias Pancreáticas/tratamiento farmacológico , Prohibitinas , Arginina Deiminasa Proteína-Tipo 2/antagonistas & inhibidores , Arginina Deiminasa Proteína-Tipo 3/antagonistas & inhibidores , Arginina Deiminasa Proteína-Tipo 4/antagonistas & inhibidores , Arginina Deiminasa Proteína-Tipo 4/metabolismoRESUMEN
Hepatic encephalopathy (HE) is a debilitating neurological complication of cirrhosis. By definition, HE is considered a reversible disorder, and therefore HE should resolve following liver transplantation (LT). However, persisting neurological complications are observed in as many as 47% of LT recipients. LT is an invasive surgical procedure accompanied by various perioperative factors such as blood loss and hypotension which could influence outcomes post-LT. We hypothesize that minimal HE (MHE) renders the brain frail and susceptible to hypotension-induced neuronal cell death. Six-week bile duct-ligated (BDL) rats with MHE and respective SHAM-controls were used. Several degrees of hypotension (mean arterial pressure of 30, 60 and 90 mm Hg) were induced via blood withdrawal from the femoral artery and maintained for 120 min. Brains were collected for neuronal cell count and apoptotic analysis. In a separate group, BDL rats were treated for MHE with the ammonia-lowering strategy ornithine phenylacetate (OP; MNK-6105), administered orally (1 g/kg) for 3 weeks before induction of hypotension. Hypotension 30 and 60 mm Hg (not 90 mm Hg) significantly decreased neuronal marker expression (NeuN) and cresyl violet staining in the frontal cortex compared to respective hypotensive SHAM-operated controls as well as non-hypotensive BDL rats. Neuronal degeneration was associated with an increase in cleaved caspase-3, suggesting the mechanism of cell death was apoptotic. OP treatment attenuated hyperammonaemia, improved anxiety and activity, and protected the brain against hypotension-induced neuronal cell death. Our findings demonstrate that rats with chronic liver disease and MHE are more susceptible to hypotension-induced neuronal cell degeneration. This highlights MHE at the time of LT is a risk factor for poor neurological outcome post-transplant and that treating for MHE pre-LT might reduce this risk.
Asunto(s)
Amoníaco/metabolismo , Conductos Biliares , Hipotensión/patología , Enfermedades Neurodegenerativas/patología , Neuronas/patología , Amoníaco/sangre , Animales , Antígenos Nucleares/metabolismo , Ansiedad/psicología , Apoptosis , Conducta Animal , Caspasa 3/metabolismo , Circulación Cerebrovascular/efectos de los fármacos , Modelos Animales de Enfermedad , Encefalopatía Hepática/patología , Hiperamonemia , Ligadura , Masculino , Proteínas del Tejido Nervioso/metabolismo , Enfermedades Neurodegenerativas/metabolismo , Enfermedades Neurodegenerativas/psicología , Ornitina/análogos & derivados , Ornitina/uso terapéutico , Ratas , Ratas Sprague-DawleyRESUMEN
BACKGROUND: Ornithine transcarbamylase deficiency (OTCD) is pleomorphic congenital hyperammonemia, in which the prognosis of the patient is determined both by genotype and environmental factors. This study investigated the clinical and biochemical characteristics of OTCD patients with different prognosis. METHOD: Of 35 OTCD patients, six males deceased at the first disease-onset, 17 males survived and had controllable ammonia levels after treatment, and 12 females survived through the first disease-onset but had intractable hyperammonemia and high mortality. Fasting blood samples from patients collected at three disease stages were used for the analysis of amino acid (AA) profile, acylcarnitine profile, and micronutrients. Differences in profiles between patients and healthy controls and within patient groups were studied. RESULTS: All OTCD patients had accumulation of glutamine, homocitrulline, lysine, glutamate, cystathionine, and pipecolic acid, as well as deficiency of citrulline, tryptophan, threonine, and carnitine. For male non-survivors, most other AAs and long-chain acylcarnitines were elevated at disease onset, of which the levels of creatine, N-acetylaspartic acid, and homoarginine were remarkably high. Male survivors and female patients had most other AAs at low to normal levels. Compared with male survivors, female patients had much lower protein-intolerance, as indicated by significantly lower levels of protein consumption indicators, including essential AAs, 1-methylhistidine, acylcarnitines et al., but high levels of ammonia. Female patients still had significantly higher levels of citrulline, homocitrulline, and citrulline/arginine compared to male survivors. CONCLUSION: Unique profiles were observed in each group of OTCD patients, indicating specific physiological changes that happened to them.
Asunto(s)
Enfermedad por Deficiencia de Ornitina Carbamoiltransferasa/metabolismo , Enfermedad por Deficiencia de Ornitina Carbamoiltransferasa/fisiopatología , Adolescente , Adulto , Amoníaco/sangre , Arginina/sangre , Niño , Preescolar , China , Creatina/metabolismo , Femenino , Humanos , Hiperamonemia/fisiopatología , Lisina/sangre , Masculino , Ornitina/uso terapéutico , Enfermedad por Deficiencia de Ornitina Carbamoiltransferasa/sangre , Urea/sangre , Adulto JovenRESUMEN
BACKGROUND AND AIM: Many evidences indicated that neutrophil extracellular traps (NETs) are involved in the pathogenesis of inflammatory bowel disease (IBD). Citrullination of histones by Protein Arginine Deiminase-4 (PAD4) is central for NETs formation. This paper aimed to explore the definite role of NETs in mouse model of Crohn's disease (CD) with 2,4,6-trinitrobenzene sulfonic acid (TNBS). METHODS: The expression of NETs-associated proteins and mRNAs in colon tissue were detected by immunohistochemistry and Real-time Quantitative PCR (QPCR) respectively. Neutrophils were isolated and stimulated in vitro to form NETs. In addition, we also administered Cl-amidine, PAD4 inhibitor, resulting in less NETs formation to investigate protective effect by measuring weight loss, gross bleeding, colon length, myeloperoxidase (MPO) activity, and cytokine expression in mice. RESULTS: The results showed enhanced expression of Ly6G, citrullinated histone H3 (CitH3), and PAD4 in TNBS-induced colitis mice and higher ability of neutrophil to produce NETs in vitro. Blocking NETs formation through Cl-amidine effectively alleviated the clinical colitis index and tissue inflammation in TNBS mice, regulated the expression of pro- or anti-inflammatory cytokines. In addition, Cl-amidine reduced the gene expression of PAD4 and the expression of NETs-associated proteins in the colon of TNBS mice and inhibited the formation of NETs in vitro. CONCLUSIONS: Our data showed that Cl-amidine could alleviate the clinical colitis index in TNBS mice to some extend and suggested blocking NETs formation through inhibition of PAD4 as therapeutic targets for the treatment of CD.
Asunto(s)
Antiinflamatorios/uso terapéutico , Colitis/tratamiento farmacológico , Enfermedad de Crohn/tratamiento farmacológico , Ornitina/análogos & derivados , Arginina Deiminasa Proteína-Tipo 4/antagonistas & inhibidores , Animales , Antiinflamatorios/farmacología , Colitis/inducido químicamente , Colitis/inmunología , Colitis/patología , Colon/efectos de los fármacos , Colon/inmunología , Colon/patología , Enfermedad de Crohn/inducido químicamente , Enfermedad de Crohn/inmunología , Enfermedad de Crohn/patología , Citocinas/sangre , Citocinas/genética , Citocinas/inmunología , Modelos Animales de Enfermedad , Trampas Extracelulares/efectos de los fármacos , Femenino , Ratones Endogámicos BALB C , Ornitina/farmacología , Ornitina/uso terapéutico , Arginina Deiminasa Proteína-Tipo 4/inmunología , Ácido TrinitrobencenosulfónicoRESUMEN
Despite widespread use of lactulose and rifaximin for the treatment of hepatic encephalopathy, this complication of advanced liver disease remains a major burden on the health care system in the United States and continues to predispose to high morbidity and mortality. Several agents have surfaced over recent years with promise to treat hepatic encephalopathy and mitigate the cognitive impairment associated with this disease process. The purpose of this article is to highlight the leading emerging therapies in hepatic encephalopathy as well as their therapeutic targets.
Asunto(s)
Trasplante de Microbiota Fecal , Encefalopatía Hepática/terapia , Acetilcarnitina/uso terapéutico , Albúminas/uso terapéutico , Amoníaco/sangre , Dipéptidos/uso terapéutico , Flumazenil/uso terapéutico , Moduladores del GABA/uso terapéutico , Glicerol/análogos & derivados , Glicerol/uso terapéutico , Encefalopatía Hepática/sangre , Encefalopatía Hepática/etiología , Humanos , Nootrópicos/uso terapéutico , Ornitina/análogos & derivados , Ornitina/uso terapéutico , Fenilbutiratos/uso terapéutico , Polietilenglicoles/uso terapéutico , Probióticos , Tensoactivos/uso terapéuticoRESUMEN
The mortality of burn patients with sepsis is higher than that of trauma patients. Sepsis causes liver dysfunction, which is an independent risk factor for multiple organ dysfunction syndrome and sepsis-induced death. We present the case of a 57-year-old female with burns covering 59% of her total body surface area and the presence of full-thickness burns. She was transferred to our burn center due to the appearance of fever and skin jaundice during the previous treatment. Based on the clinical manifestation, two main strategies were performed: debridement to remove necrotic wound tissue and treatment with a combination of drugs for liver protection. The patient's condition appeared stable for a period thereafter. Skin grafting to cover the wound was unexpectedly followed by a rapid deterioration in clinical manifestation. We can learn from this failed case that jaundice might be a sign of a systemic crisis. In such cases, surgery could aggravate the severity of the condition and cause multiple organ dysfunction syndrome. Therefore, jaundice may be a sign that skin surgery is not the best option. The optimal treatment should enhance liver protection or provide artificial liver support systems to facilitate the recovery of the liver from severe sepsis. This case suggests that skin graft surgery should not be conducted until jaundice is resolved in burn patients.
Asunto(s)
Quemaduras/complicaciones , Quemaduras/terapia , Ictericia/etiología , Ictericia/prevención & control , Ácido Aspártico/uso terapéutico , Unidades de Quemados , Quimioterapia Combinada , Medicamentos Herbarios Chinos/uso terapéutico , Femenino , Humanos , Persona de Mediana Edad , Ornitina/uso terapéutico , Silimarina/uso terapéutico , Trasplante de Piel/efectos adversos , Ácido Ursodesoxicólico/uso terapéuticoRESUMEN
BACKGROUND: Tamoxifen resistance presents a huge clinical challenge for breast cancer patients. An understanding of the mechanisms of tamoxifen resistance can guide development of efficient therapies to prevent drug resistance. METHODS: We first tested whether peptidylarginine deiminase 2 (PAD2) may be involved in tamoxifen-resistance in breast cancer cells. The effect of depleting or inhibiting PAD2 in tamoxifen-resistant MCF-7 (MCF7/TamR) cells was evaluated both in vitro and in vivo. We then investigated the potential of Cl-amidine, a PAD inhibitor, to be used in combination with tamoxifen or docetaxel, and further explored the mechanism of the synergistic and effective drug regimen of PADs inhibitor and docetaxel on tamoxifen-resistant breast cancer cells. RESULTS: We report that PAD2 is dramatically upregulated in tamoxifen-resistant breast cancer. Depletion of PAD2 in MCF7/TamR cells facilitated the sensitivity of MCF7/TamR cells to tamoxifen. Moreover, miRNA-125b-5p negatively regulated PAD2 expression in MCF7/TamR cells, therefore overexpression of miR-125b-5p also increased the cell sensitivity to tamoxifen. Furthermore, inhibiting PAD2 with Cl-amidine not only partially restored the sensitivity of MCF7/TamR cells to tamoxifen, but also more efficiently enhanced the efficacy of docetaxel on MCF7/TamR cells with lower doses of Cl-amidine and docetaxel both in vivo and in vivo. We then showed that combination treatment with Cl-amidine and docetaxel enhanced p53 nuclear accumulation, which synergistically induced cell cycle arrest and apoptosis. Meanwhile, p53 activation in the combination treatment also accelerated autophagy processes by synergistically decreasing the activation of Akt/mTOR signaling, thus enhancing the inhibition of proliferation. CONCLUSION: Our results suggest that PAD2 functions as an important new biomarker for tamoxifen-resistant breast cancers and that inhibiting PAD2 combined with docetaxel may offer a new approach to treatment of tamoxifen-resistant breast cancers.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Docetaxel/farmacología , Arginina Deiminasa Proteína-Tipo 2/antagonistas & inhibidores , Tamoxifeno/farmacología , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Apoptosis , Autofagia , Neoplasias de la Mama/enzimología , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Proliferación Celular , Docetaxel/uso terapéutico , Resistencia a Antineoplásicos , Femenino , Humanos , Células MCF-7 , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Ornitina/análogos & derivados , Ornitina/farmacología , Ornitina/uso terapéutico , Arginina Deiminasa Proteína-Tipo 2/genética , Arginina Deiminasa Proteína-Tipo 2/metabolismo , Tamoxifeno/uso terapéutico , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Oligo-peptides, including monomeric amino acids, have received much attention as bioactive molecules and drugs. One of the biggest problems of these compounds, however, is their very short bioavailability due to instant metabolism and rapid excretion. To solve this problem, we newly designed a poly(ethylene glycol) (PEG)-block-polypeptide self-assembling based drug for the treatment of acute liver injury. Here, PEG-block-poly(L-Ornithine) (PEG-b-POrn) was synthesized via a ring opening polymerization, and a nano-sized polyion self-assembling complex (NanoOrn) was prepared by simply mixing polycationic PEG-b-POrn with polyanionic chondroitin sulfate. The obtained NanoOrn was quite stable under high ionic strength and different pH conditions and NanoOrn exhibited extremely low toxicity in vitro and in vivo as compared to the original PEG-b-POrn. As compared to monomeric L-ornithine, administration of NanoOrn to mice significantly improved bioavailability of liberated ornithine, especially in the liver. Interestingly, NanoOrn treatment in acetaminophen (APAP)-induced acute liver injury mice remarkably suppressed blood ammonia levels and liver injury markers, resulting in more effective improvement of liver damage compared to monomeric ornithine via activation of ornithine transcarbomylase. These results show that the self-assembling polypeptide NanoOrn may provide a new concept and promising therapeutics as nanomedicines.
Asunto(s)
Amoníaco/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Hiperamonemia/prevención & control , Nanopartículas/química , Acetaminofén/toxicidad , Animales , Bovinos , Supervivencia Celular/efectos de los fármacos , Enfermedad Hepática Inducida por Sustancias y Drogas/complicaciones , Sulfatos de Condroitina/química , Modelos Animales de Enfermedad , Sistemas de Liberación de Medicamentos/métodos , Células Endoteliales/efectos de los fármacos , Hiperamonemia/etiología , Macrófagos/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos ICR , Nanopartículas/administración & dosificación , Ornitina/administración & dosificación , Ornitina/uso terapéutico , Células RAW 264.7RESUMEN
BACKGROUND: Hepatic encephalopathy is a common complication of cirrhosis, with high related morbidity and mortality. Its presence is associated with a wide spectrum of change ranging from clinically obvious neuropsychiatric features, known as 'overt' hepatic encephalopathy, to abnormalities manifest only on psychometric or electrophysiological testing, 'minimal' hepatic encephalopathy. The exact pathogenesis of the syndrome is unknown but ammonia plays a key role. Drugs that specifically target ammonia include sodium benzoate, glycerol phenylbutyrate, ornithine phenylacetate, AST-120 (spherical carbon adsorbent), and polyethylene glycol. OBJECTIVES: To evaluate the beneficial and harmful effects of pharmacotherapies that specifically target ammonia versus placebo, no intervention, or other active interventions, for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. SEARCH METHODS: We searched the Cochrane Hepato-Biliary Controlled Trials Register, CENTRAL, MEDLINE, Embase, and three other databases to March 2019. We also searched online trials registries such as ClinicalTrials.gov, European Medicines Agency, WHO International Clinical Trial Registry Platform, and the Food and Drug Administration for ongoing or unpublished trials. In addition, we searched conference proceedings, checked bibliographies, and corresponded with investigators. SELECTION CRITERIA: We included randomised clinical trials comparing sodium benzoate, glycerol phenylbutyrate, ornithine phenylacetate, AST-120, and polyethylene glycol versus placebo or non-absorbable disaccharides, irrespective of blinding, language, or publication status. We included participants with minimal or overt hepatic encephalopathy or participants who were at risk of developing hepatic encephalopathy. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data from the included reports. The primary outcomes were mortality, hepatic encephalopathy, and serious adverse events. We undertook meta-analyses and presented results using risk ratios (RR) or mean differences (MD), both with 95% confidence intervals (CIs), and I2 statistic values as a marker of heterogeneity. We assessed bias control using the Cochrane Hepato-Biliary domains and the certainty of the evidence using GRADE. MAIN RESULTS: We identified 11 randomised clinical trials that fulfilled our inclusion criteria. Two trials evaluated the prevention of hepatic encephalopathy while nine evaluated the treatment of hepatic encephalopathy. The trials assessed sodium benzoate (three trials), glycerol phenylbutyrate (one trial), ornithine phenylacetate (two trials), AST-120 (two trials), and polyethylene glycol (three trials). Overall, 499 participants received these pharmacotherapies while 444 participants received a placebo preparation or a non-absorbable disaccharide. We classified eight of the 11 trials as at 'high risk of bias' and downgraded the certainty of the evidence to very low for all outcomes.Eleven trials, involving 943 participants, reported mortality data, although there were no events in five trials. Our analyses found no beneficial or harmful effects of sodium benzoate versus non-absorbable disaccharides (RR 1.26, 95% CI 0.49 to 3.28; 101 participants; 2 trials; I2 = 0%), glycerol phenylbutyrate versus placebo (RR 0.65, 95% CI 0.11 to 3.81; 178 participants; 1 trial), ornithine phenylacetate versus placebo (RR 0.73, 95% CI 0.35 to 1.51; 269 participants; 2 trials; I2 = 0%), AST-120 versus lactulose (RR 1.05, 95% CI 0.59 to 1.85; 41 participants; 1 trial), or polyethylene glycol versus lactulose (RR 0.50, 95% CI 0.09 to 2.64; 190 participants; 3 trials; I2 = 0%).Seven trials involving 521 participants reported data on hepatic encephalopathy. Our analyses showed a beneficial effect of glycerol phenylbutyrate versus placebo (RR 0.57, 95% CI 0.36 to 0.90; 178 participants; 1 trial; number needed to treat for an additional beneficial outcome (NNTB) 6), and of polyethylene glycol versus lactulose (RR 0.19, 95% CI 0.08 to 0.44; 190 participants; 3 trials; NNTB 4). We did not observe beneficial effects in the remaining three trials with extractable data: sodium benzoate versus non-absorbable disaccharides (RR 1.22, 95% CI 0.51 to 2.93; 74 participants; 1 trial); ornithine phenylacetate versus placebo (RR 2.71, 95% CI 0.12 to 62.70; 38 participants; 1 trial); or AST-120 versus lactulose (RR 1.05, 95% CI 0.59 to 1.85; 41 participants; 1 trial).Ten trials, involving 790 participants, reported a total of 130 serious adverse events. Our analyses found no evidence of beneficial or harmful effects of sodium benzoate versus non-absorbable disaccharides (RR 1.08, 95% CI 0.44 to 2.68; 101 participants; 2 trials), glycerol phenylbutyrate versus placebo (RR 1.63, 95% CI 0.85 to 3.13; 178 participants; 1 trial), ornithine phenylacetate versus placebo (RR 0.92, 95% CI 0.62 to 1.36; 264 participants; 2 trials; I2 = 0%), or polyethylene glycol versus lactulose (RR 0.57, 95% CI 0.18 to 1.82; 190 participants; 3 trials; I2 = 0%). Likewise, eight trials, involving 782 participants, reported a total of 374 non-serious adverse events and again our analyses found no beneficial or harmful effects of the pharmacotherapies under review when compared to placebo or to lactulose/lactitol.Nine trials, involving 733 participants, reported data on blood ammonia. We observed significant reductions in blood ammonia in placebo-controlled trials evaluating sodium benzoate (MD -32.00, 95% CI -46.85 to -17.15; 16 participants; 1 trial), glycerol phenylbutyrate (MD -12.00, 95% CI -23.37 to -0.63; 178 participants; 1 trial), ornithine phenylacetate (MD -27.10, 95% CI -48.55 to -5.65; 231 participants; 1 trial), and AST-120 (MD -22.00, 95% CI -26.75 to -17.25; 98 participants; 1 trial). However, there were no significant differences in blood ammonia concentrations in comparison with lactulose/lactitol with sodium benzoate (MD 9.00, 95% CI -1.10 to 19.11; 85 participants; 2 trials; I2 = 0%), AST-120 (MD 5.20, 95% CI -2.75 to 13.15; 35 participants; 1 trial), and polyethylene glycol (MD -29.28, 95% CI -95.96 to 37.39; 90 participants; 2 trials; I2 = 88%). FUNDING: Five trials received support from pharmaceutical companies while four did not; two did not provide this information. AUTHORS' CONCLUSIONS: There is insufficient evidence to determine the effects of these pharmacotherapies on the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. They have the potential to reduce blood ammonia concentrations when compared to placebo, but their overall effects on clinical outcomes of interest and the potential harms associated with their use remain uncertain. Further evidence is needed to evaluate the potential beneficial and harmful effects of these pharmacotherapies in this clinical setting.
Asunto(s)
Amoníaco/antagonistas & inhibidores , Encefalopatía Hepática/tratamiento farmacológico , Encefalopatía Hepática/prevención & control , Cirrosis Hepática/complicaciones , Adulto , Carbono/uso terapéutico , Causas de Muerte , Femenino , Glicerol/efectos adversos , Glicerol/análogos & derivados , Glicerol/uso terapéutico , Humanos , Lactulosa/uso terapéutico , Masculino , Persona de Mediana Edad , Ornitina/efectos adversos , Ornitina/análogos & derivados , Ornitina/uso terapéutico , Óxidos/uso terapéutico , Fenilbutiratos/efectos adversos , Fenilbutiratos/uso terapéutico , Placebos/uso terapéutico , Polietilenglicoles/efectos adversos , Polietilenglicoles/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Benzoato de Sodio/efectos adversos , Benzoato de Sodio/uso terapéuticoRESUMEN
Carbamylation (or carbamoylation) is a non-enzymatic post-translational modification process of lysine residues and protein N-termini, which occurs throughout the lifespan of both various plasma proteins and low-density lipoprotein (LDL) particles. Carbamylation results from the binding of isocyanates spontaneously derived from high levels of blood urea, environmental pollutants, nutritional sources and leads to the formation of potentially atherogenic carbamylated-LDL (c-LDL) particles. The carbamylation of LDL apolipoproteins is associated unfavorable downstream effects. Ornithine is a non-proteinogenic amino acid, which plays a central role at the urea cycle function. The primary use of ornithine in supplements is to support athletic performance, liver function and wound recovery. Ornithine is structurally highly similar to lysine, and is only one carbon atom shorter in its side-chain. Therefore, we hypothesize that supplemented ornithine could compete with ε-amino groups of lysine residues found in apolipoproteins of native LDL particles in their binding to isocyanates and decrease c-LDL formation. This issue still remains unresolved in current literature and needs to be elucidated in experimental studies.
Asunto(s)
Aminoácidos/metabolismo , Aterosclerosis/metabolismo , Aterosclerosis/terapia , Lipoproteínas LDL/metabolismo , Ornitina/uso terapéutico , Carbamilación de Proteína , Apolipoproteína B-100/química , Apolipoproteínas/química , Aterosclerosis/fisiopatología , Humanos , Lisina/química , Modelos Biológicos , Ornitina/químicaRESUMEN
PURPOSE OF REVIEW: Hepatic encephalopathy is one of the most debilitating clinical manifestations of cirrhosis and associated with increased morbidity and mortality. Treatment modalities available include the nonabsorbable disaccharides (lactulose) and the nonabsorbable antibiotics (rifaximin). RECENT FINDINGS: Newer therapeutic targets under evaluation include ammonia scavengers (ornithine phenylacetate) and modulation of gut microbiota (fecal microbiota transplantation). SUMMARY: This review will focus on the pathophysiology of hepatic encephalopathy along with an update on therapeutic targets under investigation.
Asunto(s)
Trasplante de Microbiota Fecal/métodos , Fármacos Gastrointestinales/uso terapéutico , Encefalopatía Hepática/terapia , Aminoácidos Aromáticos/metabolismo , Aminoácidos de Cadena Ramificada/uso terapéutico , Amoníaco/metabolismo , Dipéptidos/uso terapéutico , Fragilidad/epidemiología , Microbioma Gastrointestinal , Glicerol/análogos & derivados , Glicerol/uso terapéutico , Encefalopatía Hepática/epidemiología , Encefalopatía Hepática/etiología , Encefalopatía Hepática/metabolismo , Humanos , Hipertensión Portal/complicaciones , Hipertensión Portal/metabolismo , Lactulosa/uso terapéutico , Cirrosis Hepática/complicaciones , Cirrosis Hepática/metabolismo , Ornitina/análogos & derivados , Ornitina/uso terapéutico , Fenilbutiratos/uso terapéutico , Polietilenglicoles/uso terapéutico , Probióticos/uso terapéutico , Rifaximina/uso terapéutico , Oligoelementos/uso terapéutico , Zinc/uso terapéuticoRESUMEN
Objective: To explore the relevance of citrullinated proteins and anti-citrullinated protein antibodies (ACPA) via protein arginine deiminase (PAD) inhibition in peptide glucose-6-phosphate isomerase-induced arthritis (pGIA).Methods: Cl-amidine, a PAD inhibitor, was injected into pGIA. Clinical scores and histopathological findings of ankle joints were assessed. Serum ACPA titers were analyzed using ELISA. Citrullinated protein expression in joints and sera were examined with immunohistochemistry and Western blot analysis, respectively. Serum levels of IL-6, TNFα, and IL-1ß were measured with cytometric bead array (CBA). Gene expression levels of IL-6 and TNFα in joints, lymph nodes, and spleens were analyzed with quantitative PCR. GPI-specific productions of IFNγ and IL-17 from T cells in lymph nodes were evaluated.Results: Cl-amidine treatment significantly reduced arthritis severity while ACPA titers tended to be lower, but not significantly different compared to the control. Citrullinated proteins in joints and sera from treated mice were clearly decreased. With Cl-amidine treatment, serum IL-6 levels were significantly decreased, and IL-6 and TNFα gene expression were significantly reduced in joints. IL-17 production from GPI-specific T cells tended to be lower in Cl-amidine-treated mice, but not significantly different.Conclusion: Our results suggested that PAD-mediated citrullinated protein was involved in the pathogenesis of arthritis via IL-6.